Research programme: matriptase inhibitors - Amgen/Dendreon

Drug Profile

Research programme: matriptase inhibitors - Amgen/Dendreon

Latest Information Update: 08 Sep 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen; Dendreon Corporation
  • Class Monoclonal antibodies
  • Mechanism of Action Matriptase inhibitors; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 08 Sep 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 03 Apr 2006 Abgenix has been acquired and merged into Amgen
  • 05 Jan 2004 The activities of Dendreon San Diego LLC are being relocated to Dendreon's Seattle headquarters
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top